HRSA-23-068: Maternal and Child Health Secondary Data Analysis Research (MCH SDAR)
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2022.
Health Resources and Services Administration offered grants of up to $120,000 to nonprofits, colleges and universities and tribes. It expected to make about 5 awards worth $600,000 in total. Applications closed on February 13, 2023.
From the official notice on Grants.gov, last changed December 12, 2022. Checked November 7, 2026.
- Award ceiling$120,000
- Total funding$600,000
- Expected awards5
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-22-096 | October 28, 2021 | Closed January 26, 2022 | Closed |
Key dates
| Posted | November 14, 2022 |
|---|---|
| Deadline | February 13, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities and tribes.
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility is limited to public or non-profit institutions of higher learning and public or private non-profit agencies engaged in research or in programs relating to maternal and child health and/or services for children with special health care needs. See 42 CFR 51a.3 (b). Faith-based and community-based organizations, tribes, and tribal organizations are eligible to apply.
Is this a realistic fit?
- Past Special Projects of Regional and National Significance awards averaged $1.6 million; this notice allows up to $120,000 per award.
- No cost sharing or match is required.
What the grant funds
The purpose of the SDAR program is to support research that analyzes existing national data sets and/or administrative records to answer questions that can improve the health and well-being of MCH populations, including children and teenagers with autism spectrum disorders and other developmental disabilities (ASD/DD). The SDAR program helps researchers use existing data sets to identify new issues, study new research questions, test hypotheses, and determine pathways for intervention. Existing and new public health challenges affecting MCH populations, including children with special health care needs (MCH SDAR) and children and adolescents with ASD/DD (Autism SDAR), require timely, evidence-based responses from programs, policy, and practice. Without sufficient evidence or data, it is hard to develop interventions addressing both existing and new issues. SDAR research projects should help address any of the following HRSA’s Strategic Plan Objectives: • 1.4 Incorporate health equity concepts and measures into programs and policies; • 2.3 Improve the quality, safety, and effectiveness of health services for underserved populations and those in need; and • 2.4 Enhance maternal and child health efforts and reduce disparities in morbidity, mortality, and health outcomes.
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-23-068 still open?
No. It closed on February 13, 2023. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for Maternal and Child Health Secondary Data Analysis Research (MCH SDAR)?
Health Resources and Services Administration accepted applications from nonprofits, colleges and universities and tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Maternal and Child Health Secondary Data Analysis Research (MCH SDAR)?
Closed February 13, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $120,000 each. About $600,000 in total across about 5 awards.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)